Sekar Kathiresan - Oct 3, 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, Attorney-in-Fact for Sekar Kathiresan
Stock symbol
VERV
Transactions as of
Oct 3, 2022
Transactions value $
-$1,613,122
Form type
4
Date filed
10/5/2022, 05:00 PM
Previous filing
Aug 11, 2022
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Options Exercise $69.5K +50K +15.73% $1.39* 368K Oct 3, 2022 Direct
transaction VERV Common Stock Sale -$955K -28.9K -7.86% $33.02 339K Oct 3, 2022 Direct F1, F2
transaction VERV Common Stock Sale -$382K -11.2K -3.3% $34.13 328K Oct 3, 2022 Direct F1, F3
transaction VERV Common Stock Sale -$346K -9.9K -3.02% $34.97 318K Oct 3, 2022 Direct F1, F4
holding VERV Common Stock 241K Oct 3, 2022 Kathiresan Family 2021 Irrevocable Trust
holding VERV Common Stock 81K Oct 3, 2022 Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Options Exercise $0 -50K -26.46% $0.00 139K Oct 3, 2022 Common Stock 50K $1.39 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.59 to $33.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) of this Form 4.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.59 to $34.59, inclusive.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.61 to $35.50, inclusive.
F5 The remaining shares underlying this option, which was granted on April 15, 2019, vest in equal monthly installments until March 25, 2024.